Wordt geladen...
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who...
Bewaard in:
| Gepubliceerd in: | Ann Oncol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6503622/ https://ncbi.nlm.nih.gov/pubmed/30715153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz011 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|